These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 30203268

  • 1. Microvascular Density and Circulating Endothelial Progenitor Cells Before and After Treatment with Incretin Mimetics in Diabetic Patients.
    De Ciuceis C, Agabiti-Rosei C, Rossini C, Caletti S, Coschignano MA, Ferrari-Toninelli G, Ragni G, Cappelli C, Cerudelli B, Airò P, Scarsi M, Tincani A, Porteri E, Rizzoni D.
    High Blood Press Cardiovasc Prev; 2018 Dec; 25(4):369-378. PubMed ID: 30203268
    [Abstract] [Full Text] [Related]

  • 2. GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.
    Smits MM, Tonneijck L, Muskiet MH, Hoekstra T, Kramer MH, Diamant M, Serné EH, van Raalte DH.
    Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2125-32. PubMed ID: 27562916
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the effects of twice-daily exenatide and insulin on carotid intima-media thickness in type 2 diabetes mellitus patients: a 52-week randomized, open-label, controlled trial.
    Zhang J, Xian TZ, Wu MX, Li C, Pan Q, Guo LX.
    Cardiovasc Diabetol; 2020 Apr 25; 19(1):48. PubMed ID: 32334592
    [Abstract] [Full Text] [Related]

  • 4. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF, Mannucci E, Ahrén B.
    Diabetes Obes Metab; 2012 Aug 25; 14(8):762-7. PubMed ID: 22471248
    [Abstract] [Full Text] [Related]

  • 5. Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation.
    Yu M, Xie J, Fernandez Lando L, Kabul S, Swindle RW.
    Clin Ther; 2016 Jan 01; 38(1):149-60. PubMed ID: 26706658
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of the Use of Exenatide Once-Weekly Suspension Autoinjector Among Patients With Type 2 Diabetes Mellitus and Health Care Professionals.
    LaRue S, Springer J, Noderer M, Meehan J, Wysham CH.
    J Diabetes Sci Technol; 2019 Mar 01; 13(2):226-234. PubMed ID: 30234374
    [Abstract] [Full Text] [Related]

  • 7. Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes.
    Aung MM, Slade K, Freeman LAR, Kos K, Whatmore JL, Shore AC, Gooding KM.
    Diabetologia; 2019 Sep 01; 62(9):1701-1711. PubMed ID: 31203378
    [Abstract] [Full Text] [Related]

  • 8. Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg.
    Malmenäs M, Bouchard JR, Langer J.
    Clin Ther; 2013 Jun 01; 35(6):795-807. PubMed ID: 23642290
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. beta-cell failure in diabetes and preservation by clinical treatment.
    Wajchenberg BL.
    Endocr Rev; 2007 Apr 01; 28(2):187-218. PubMed ID: 17353295
    [Abstract] [Full Text] [Related]

  • 11. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Drucker DJ, Nauck MA.
    Lancet; 2006 Nov 11; 368(9548):1696-705. PubMed ID: 17098089
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes.
    Smits MM, Tonneijck L, Muskiet MH, Hoekstra T, Kramer MH, Pieters IC, Cahen DL, Diamant M, van Raalte DH.
    BMJ Open; 2015 Nov 19; 5(11):e009579. PubMed ID: 26586327
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Liraglutide suppresses non-esterified free fatty acids and soluble vascular cell adhesion molecule-1 compared with metformin in patients with recent-onset type 2 diabetes.
    Chen XM, Zhang WQ, Tian Y, Wang LF, Chen CC, Qiu CM.
    Cardiovasc Diabetol; 2018 Apr 10; 17(1):53. PubMed ID: 29636047
    [Abstract] [Full Text] [Related]

  • 16. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
    Siddiqui NI.
    Mymensingh Med J; 2009 Jan 10; 18(1):113-24. PubMed ID: 19182763
    [Abstract] [Full Text] [Related]

  • 17. Incretin hormone mimetics and analogues in diabetes therapeutics.
    Green BD, Flatt PR.
    Best Pract Res Clin Endocrinol Metab; 2007 Dec 10; 21(4):497-516. PubMed ID: 18054732
    [Abstract] [Full Text] [Related]

  • 18. Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors.
    Mathieu C, Bollaerts K.
    Int J Clin Pract Suppl; 2007 Aug 10; (154):29-37. PubMed ID: 17593275
    [Abstract] [Full Text] [Related]

  • 19. [Twice-daily and weekly exenatide: Clinical profile of two pioneer formulations in incretin therapy].
    Lecube A, Bueno M, Suárez X.
    Med Clin (Barc); 2014 Aug 10; 143 Suppl 2():23-7. PubMed ID: 25326840
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.